2023. Adaptive Licensing and Conditional Approval: A Perspective on Evidence Owed After Market Entry. Translational Medicine & Therapeutics Journal. 2, 2 (Nov. 2023), 92–100. DOI:https://doi.org/10.5281/zenodo.22649112.